Biologic Therapies in Sarcoidosis and Uveitis: A Review
Open Access
- 7 July 2020
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 12 (7) , e9057
Abstract
Sarcoidosis and uveitis are chronic inflammatory conditions with potentially debilitating effects on quality of life. Steroids form the mainstay standard therapy in both conditions. Biologic agents are considered to be appropriate alternatives for treatment in steroid-refractory sarcoidosis and uveitis due to the role of tumor necrosis factor (TNF) in mediating the inflammatory cascade seen in both conditions. We performed a thorough literature search using PubMed to compare the extent of use, efficacy, and safety profile of individual anti-TNF agents in the management of these conditions. Our review consists of two systematic reviews with meta-analysis, thirteen observational studies, and fifteen case series/reports. Infliximab had the widest range of organ-system usage in extra-pulmonary sarcoidosis but is equivalent to adalimumab in terms of efficacy. In uveitis, adalimumab was found to be the most efficacious agent for maintaining disease remission in adults and children with chronic non-infectious uveitis. Etanercept was neither used widely, nor was it efficacious in the management of either condition. In terms of safety profile, biologic agents were found to be well tolerated and have a similar safety profile. More randomized clinical trials are needed to inform evidence-based use of biologic agents in these conditions.Keywords
This publication has 41 references indexed in Scilit:
- Early administration of adalimumab for paediatric uveitis due to Behçet’s diseasePediatric Rheumatology, 2019
- The rescue effect of adalimumab in the treatment of refractory pediatric panuveitis complicated with steroid-induced glaucomaTaiwan Journal of Ophthalmology, 2018
- Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis NetworkArthritis & Rheumatology, 2016
- Pediatric gastrointestinal sarcoidosis: Successful treatment with infliximabSaudi Journal of Gastroenterology, 2016
- Current Evidence of Anti–Tumor Necrosis Factor α Treatment Efficacy in Childhood Chronic Uveitis: A Systematic Review and Meta‐Analysis Approach of Individual DrugsArthritis Care & Research, 2014
- No impact of tumor necrosis-factor antagonists on the joint manifestations of sarcoidosisInternational Journal of General Medicine, 2013
- Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitisGraefe's Archive for Clinical and Experimental Ophthalmology, 2011
- Infliximab for treating sarcoidosis patients, Portuguese experienceRevista Portuguesa de Pneumologia (English Edition), 2011
- Disfiguring Annular Sarcoidosis Improved by AdalimumabCase Reports in Dermatology, 2011
- Incidence and prevalence of uveitis in Northern California The Northern California Epidemiology of Uveitis StudyOphthalmology, 2004